About GenTel BioSciences
GenTel BioSciences is engaged in biochip and protein microarray technologies. The company's platform has focused on surface chemistry technologies for the purpose of detecting and measuring proteins. The application of miniaturized tests utilizing GenTel's thin-film nitrocellulose surface has served to deliver new standards in biomedical discovery, medical care, and pre-clinical drug development. In March 2012, GenTel BioSciences ceased operations due to bankruptcy. In May 2012, Intuitive Biosciends acquired the animal health and research tools assets and businesses of GenTel BioSciences. The assets include products for testing non-human primates, including the Colony Surveillance Assays and a screening test for tuberculosis.
Latest GenTel BioSciences News
Feb 3, 2014
USDM Life Sciences Hires FDA's Unique Device Identification Architect, Jay Crowley as Vice President of UDI Practice KromaTiD, Inc. announces that Alex D. Vodenlich of Madison, WI, will be joining as its chief executive officer. Mr. Vodenlich is an executive with over twenty years experience in the life science industry. He is the former President and CEO of Gentel Biosciences, Inc., a provider of multiplex immunoassay technologies. "We chose Alex because of his successes in fundraising, sales and marketing of research reagents, and early-stage company development, all of which make him an exceptional fit for KromaTiD. He impressed us as a passionate, action-oriented leader, and someone who brings directly relevant commercialization experience to address the markets KromaTiD is seeking to serve" said Dr. Opgenorth, chairman of the company’s board of directors. “He is committed and passionate about building successful life science companies and will be a strong addition to the Colorado bioscience community. " During his tenure with Gentel, Mr. Vodenlich raised angel and other private equity funding totaling more than $15 million to develop and commercialize a proprietary protein array platform that served research and clinical laboratory markets. “I am excited to be a part of this promising venture. The company has the right mix of protected intellectual property, product development and validation, market opportunity, management team experience, and community resources to be successful,” said Vodenlich. “Launched in the fall of 2013, KromaTiD’s dGH™ assays are already providing major research laboratories with powerful tools for understanding the roots of genetic diseases. With investor support, our goals in 2014 and beyond will be to build revenue traction and to initiate collaborations with strategic commercial partners.” Prior to Gentel, Mr. Vodenlich served as the Vice President of Sales and Marketing for PanVera Corporation from 1993-2003, a research products company that was acquired by Life Technologies. He was one of the first 10 employees at PanVera and played a key role in developing their successful sales strategy. Prior to PanVera he was employed as a discovery research scientist with Pfizer and Abbott Laboratories, and he holds Bachelor’s and Master’s degrees from the University of Wisconsin-Madison. KromaTiD, Inc. KromaTiD, Inc. is a Colorado-based bioscience company dedicated to creating new products for disease research, mutation detection and chromosome analysis. KromaTiD’s patented dGH™ chromosome imaging platform provides disease researchers with the ability to detect all types of DNA rearrangements including previously undetectable classes of mutations. The company and its collaborators (including NASA, the State of Colorado Office of Economic Development and International Trade, and the Colorado Institute of Drug, Device and Diagnostic Development) expect that KromaTiD products will pave the way to identifying new diagnostic targets, developing a better understanding of the genetic causes of a variety of important human diseases, and providing more informed genetic counseling. KromaTiD develops and markets dGH technology under license from Colorado State University. For more information on products and services offered by KromaTiD, visit http://www.kromatid.com . For the original version on PRWeb visit: http://www.prweb.com/releases/2014/02/prweb11541683.htm
GenTel BioSciences Frequently Asked Questions (FAQ)
When was GenTel BioSciences founded?
GenTel BioSciences was founded in 2000.
Where is GenTel BioSciences's headquarters?
GenTel BioSciences's headquarters is located at 5500 Nobel Drive, Madison.
What is GenTel BioSciences's latest funding round?
GenTel BioSciences's latest funding round is Asset Sale.
Who are the investors of GenTel BioSciences?
Investors of GenTel BioSciences include Intuitive Biosciences, Wisconsin Investment Partners, Kegonsa Capital Partners, NEW Capital Fund and Affymetrix.
Who are GenTel BioSciences's competitors?
Competitors of GenTel BioSciences include Pepscan, ProteinSimple, BioVidria, Protein Discovery, Solidus Biosciences and 7 more.
Compare GenTel BioSciences to Competitors
Solidus Biosciences is a company focused on providing business intelligence in the pharmaceutical and biologic drugs sector. The company's main services include offering insights on life cycle management, brand erosion, generic entry, biosimilars, patents, sales, litigation, and more, all related to pharmaceutical and biologic drugs. The company primarily serves the biopharmaceutical industry. It is based in Troy, New York.
Oxford Molecular aims to provide computational chemistry and molecular graphics to European and U.S. markets.
Allozyne is a protein optimization company committed to the development of improved biological therapeutics to treat multiple areas of unmet medical need. Allozyne's two technology platforms enable the incorporation of amino acids analogues, at any specified position, into existing biologics leading to improved efficacy, tolerability and pharmacology.
Zyomyx is a privately held diagnostics company. It innovates develops and commercializes diagnostic platforms. The Zyomyx product development infrastructure and suite of proprietary assay and surface technologies are ideally suited for the development of affordable, disposable point-of-care diagnostic products, designed to increase access to testing. Zyomyx's first product is an advanced but simple and inexpensive CD4 T-cell point-of-care test that will be launched globally and is configured to meet the needs of developing countries. The company was founded in 1998 and is based in Fremont, California.
Chalex Corporation's precision-made chambered McMaster counting slides are used by researchers, laboratories, nematologists and veterinary practitioners throughout the world. Made of clear durable acrylic for long-lasting use, the company's slides also feature exact volumes thanks to injection-molded accuracy which yield consistent test results compared to other slides with handmade chamber spacers. The quality of these slides make them the standard the world over.
ENDEXT Technology signifies the wheat germ cell-free protein synthesis technology that was developed by Professor Yaeta Endo of Ehime University. The wheat germ lysate produced by the technology is free of translation inhibitors, and as a result, it permits remarkably stable in vitro protein synthesis: all that is needed for the synthesis is to add the target mRNA as well as the amino acids and other substrates to the lysate. The eukaryotic origin of the ENDEXT(R) wheat germ lysate has made it possible to produce a broad range of difficult-to-express proteins including not only those of microorganisms and higher forms of life but also artificial proteins. Pacific Northwest National Laboratory (PNNL), one of the nine national laboratories of the U.S. Department of Energy, employed the CFS automatic protein synthesizer GenDecoder1000. PNNL will use it to synthesize proteins required for Genomes to Life (GTL) program, whose focus is on the molecular machines of DOE-relevant microbes and their networking in living cells and microbial communities. GenDecoder1000 is capable of transcription and translation of 384 samples in an overnight campaign.